Skip to main content

Drug Interactions between Pentasa and ProQuad

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

mesalamine varicella virus vaccine

Applies to: Pentasa (mesalamine) and ProQuad (measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine)

GENERALLY AVOID: In pediatric patients, use of varicella virus vaccine during salicylate or salicylate-containing therapy may pose a theoretical risk of Reye's syndrome based on known association of the syndrome with salicylates and natural varicella infection. Children and adolescents receiving the vaccine in U.S. clinical studies were instructed not to use salicylates for six weeks after vaccination. There were no reports of Reye's syndrome during these studies.

MANAGEMENT: Vaccine recipients less than 18 years of age should avoid the use of salicylates for six weeks after immunization with varicella virus vaccine.

References

  1. "Product Information. Dipentum (olsalazine)." Meda Pharmaceuticals PROD (2001):
  2. "Product Information. Varivax (varicella virus vaccine)." Merck & Co., Inc (2022):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer